Video from AHRA 2022: Emanuel Kanal on MRI contrast relaxivity

Jul 12, 2022

Do you know the relaxivity of your MRI contrast agents? Chances are you don't, but you might want to start learning about the concept, according to Dr. Emanuel Kanal, who gave a presentation on the topic at this week's AHRA 2022 meeting.

Do you know the relaxivity of your MRI contrast agents? Chances are you don't, but you might want to start learning about the concept, according to Dr. Emanuel Kanal, who gave a presentation on the topic at this week's AHRA 2022 meeting.

What causes lung cancers to be missed on screening?

December 12, 2025

2025 12 12 Fapi Breast Cancer Thumbnail

Early PET/CT feasible in women with suspected breast cancer

December 12, 2025

Doctor Patient Consult Tablet

Study highlights risk-based breast cancer screening; ACR responds

December 12, 2025

At RSNA 2025, thoracic radiologists debated using autonomous AI for chest radiograph interpretation. They also fielded many audience questions and comments as well.

Is AI ready for autonomous reads of chest x-rays?

December 11, 2025

What causes lung cancers to be missed on screening?

By Kate Madden Yee

Incomplete smoking history documentation appears to be one of the reasons.

December 12, 2025

Early PET/CT feasible in women with suspected breast cancer

Early imaging is not only more patient-friendly but also has the potential to simplify clinical workflows.

December 12, 2025

2025 12 12 Fapi Breast Cancer Thumbnail

Study highlights risk-based breast cancer screening; ACR responds

By Amerigo Allegretto

A study showing the potential benefits of risk-based breast cancer screening has drawn criticism from the ACR.

December 12, 2025

Doctor Patient Consult Tablet

Is AI ready for autonomous reads of chest x-rays?

A debate at RSNA 2025 reviewed the current use of autonomous AI for chest radiographs and assessed future opportunities.

December 11, 2025

At RSNA 2025, thoracic radiologists debated using autonomous AI for chest radiograph interpretation. They also fielded many audience questions and comments as well.

Patients support AI in radiology, but not as a standalone reader

A majority of survey respondents would not agree to AI as a sole reader.

December 11, 2025

Lung cancer rates low on chest CT after incidental neck imaging findings

By Kate Madden Yee

The results could indicate that follow-up chest CT may not be necessary in this situation.

December 11, 2025

Adding AI to MRI improves return to play classification frameworks

By Kate Madden Yee

Predicting when athletes can safely return to play after an injury is key.

December 10, 2025

Football Players Scrimmage

Marathon training does not have long-term negative effects on heart

By Amerigo Allegretto

Echocardiography shows that endurance training by marathon runners does not have long-term negative effects on the heart.

December 10, 2025

Runner Street Thumbnail Adobe Augustas Cetkauskas

Phase I trial reveals the potential of a new PSMA-PET tracer

The radiotracer detected more lesions in men with metastatic disease than F-18 piflufolastat.

December 9, 2025

Scans in a 73-year-old man with biochemically recurrent prostate cancer (prostate-specific antigen level of 0.5 ng/mL) who underwent PET/CT with 9.4 mCi of F-18 piflufolastat and a second PET/CT examination with 8.1 mCi of copper 61-NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid)–prostate-specific membrane antigen for imaging and therapy (Cu-61 PSMA I&T) 24 days apart, with no intervening therapy. Maximum intensity projection (MIP) images obtained (A) 1 hour after F-18 piflufolastat administration and (B) 1, (C) 2, and (D) 4 hours after Cu-61 PSMA I&T administration are shown. Physiologic uptake is seen in the lacrimal glands, salivary glands, liver, spleen, kidneys, ureters, and bladder. Pathologic uptake in pelvic nodal metastases is labeled with arrows. The F-18 piflufolastat PET/CT MIP image reveals two avid pelvic nodal metastases (arrows). Cu-61 PSMA I&T PET/CT scans demonstrate three avid pelvic nodal metastases on 1-hour and 2-hour images (arrows); five avid pelvic nodal metastases were suspected on the 4-hour image (arrows).

Radiologists can designate nonmass lesions on breast ultrasound

By Amerigo Allegretto

Breast radiologists achieved moderate to substantial interreader agreement for classifying nonmass lesions on ultrasound.

December 9, 2025

Images depict a 50-year-old woman with a lesion detected during screening ultrasound. (A) Transverse and (B) longitudinal images reveal a 0.5-cm hypoechoic lesion (arrow) in the left breast. (C) Transverse color Doppler ultrasound image does not show an increase in vascularity. Two readers classified the lesion as a mass, whereas two others categorized it as a nonmass lesion, leading to its designation as a controversial nonmass lesion. Ultrasound-guided core needle biopsy and subsequent pathologic examination confirmed a nonproliferative breast change.

Long COVID's neurological effects persist

By Kate Madden Yee

Long COVID is typically defined as persistent symptoms beyond four weeks from onset of the illness.

December 9, 2025

MRI proves effective for tracking results of obesity interventions

By Kate Madden Yee

MRI is a powerful tool to monitor skeletal muscle adaptations during lifestyle interventions for obesity, researchers noted.

December 8, 2025

Page 1 of 190